Eli Lilly Announces Positive Phase 3 Results for Obesity Treatment Retatrutide
Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial of retatrutide, a once-weekly obesity treatment. The highest dose showed an average weight loss of 28.3% over 80 weeks and up to 30.3% in those with higher BMI after 104 weeks.
Tickers: $LLY
Topics: obesity treatment Phase 3 trial results retatrutide weight loss drug